Table 6.
Survivors 43 |
Non-survivors 15 |
p value | |
---|---|---|---|
Sex (male/female) | 28/15 | 8/7 | |
Age, years (mean ± SD) | 62.4 ± 14 | 60.2 ± 10.9 | 0.22 |
SAPS II, median (IQR) | 45(34–59) | 66 (55–73) | <0.003 |
SOFA, median (IQR) | 8 (6–11) | 12 (9–13) | <0.005 |
Creatininemia, median (IQR), (μmol/L) | 52 (33–100) | 46 (30–95) | 0.62 |
Positive HAA, n | 11 | 4 | |
PCT, median (IQR), (ng/mL) | 0.97 (0.27–8) | 5.2 (2–16.8) | 0.025 |
hsCRP, median (IQR), (mg/L) | 102 (65–242) | 180 (95–278) | 0.29 |
Presepsin, median (IQR), (pg/mL) | 999 (570–2020) | 1821 (1310–2837) | 0.006 |
ICU length of stay, median (IQR), (days) | 6 (4–11) | 5 (2–9) | 0.36 |
SAPS simplified acute physiology score, SOFA sequential organ failure assessment score, PCT procalcitonin, hsCRP high-sensitivity C-reactive protein
p: differences between survivor and non-survivor patients